FMOC-L-Phenylalanine
FMOC-L-Phenylalanine structure
|
Common Name | FMOC-L-Phenylalanine | ||
|---|---|---|---|---|
| CAS Number | 35661-40-6 | Molecular Weight | 387.428 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 620.1±50.0 °C at 760 mmHg | |
| Molecular Formula | C24H21NO4 | Melting Point | 180-187 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 328.8±30.1 °C | |
|
Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors.
Cancer Sci. 106 , 747-56, (2015) L-type amino acid transporter 1 (LAT1), overexpressed on the membrane of various tumor cells, is a potential target for tumor-targeting therapy. This study aimed to develop a LAT1-mediated chemotherapeutic agent. We screened doxorubicin modified by seven diff... |
|
|
In Vitro and In Vivo Efficacy of Self-Assembling RGD Peptide Amphiphiles for Targeted Delivery of Paclitaxel.
Pharm. Res. 32 , 3087-101, (2015) The objective of this work was to compare the efficacy of self-assembling cyclic and linear RGD peptide amphiphiles as carriers for delivering paclitaxel to αvβ3 integrin overexpressing tumors.Linear (C18-ADA5-RGD) and cyclic (C18-ADA5-cRGDfK) peptide amphiph... |
|
|
Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model.
Sci. Rep. 4 , 6777, (2014) Amyloid-β (Aβ) is one of the few neuropathological biomarkers associated with transporters of the blood-brain barrier (BBB). Despite the well-characterized clinical indication of decreasing Aβ levels in the cerebrospinal fluid (CSF) during the development of ... |
|
|
Design and synthesis of newN-(fluorenyl-9-methoxycarbonyl) (Fmoc)-dipeptides as anti-inflammatory agents
Eur. J. Med. Chem. 44 , 1933-40, (2009) Twenty-four new dipeptide analogs ( 1– 24) of aurantiamide acetate were designed, synthesized, and assayed for effects on superoxide anion generation and elastase release by human neutrophils in response to fMLP/CB. Among them, seven N-(fluorenyl-9-methoxycar... |